MetaCap

Aktis Oncology (AKTS) vs MoonLake Immunotherapeutics (MLTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $901.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKTS-27.90%MLTX-40.13%
+48%-2%-53%
Jan 9, 20261 yearNov 20, 2026
AKTS-27.90%MLTX-40.13%
+46%-3%-53%
Jan 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKTS versus MLTX key metrics
MetricAKTSMLTX
Share price$16.15$11.07
Market cap$901.14M$942.13M
1-day change-1.52%+0.36%
YTD return—-16.01%
1-year return—-12.63%
5-year return—+12.16%
EPS (TTM)$-1.80$-3.66
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-227.32M
52-week high$34.19$23.29
52-week low$13.96$9.46
Distance from 52-week high-52.76%-52.47%
Analyst consensusstrong_buybuy
Avg. price target upside+122.17%+173.62%
Average volume408.46K1.64M
Shares outstanding53.93M85.11M
Employees79130
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aktis Oncology

AKTS stock →

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees

About MoonLake Immunotherapeutics

MLTX stock →

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

AKTS vs MLTX FAQ

Which is bigger, Aktis Oncology or MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $901.14M for Aktis Oncology (AKTS).

Are Aktis Oncology and MoonLake Immunotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons